Skip Navigation

JNCI Journal of the National Cancer Institute 1988 80(14):1147-1151; doi:10.1093/jnci/80.14.1147
© 1988 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Canney, P. A.
Right arrow Articles by Spooner, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canney, P. A.
Right arrow Articles by Spooner, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 80, No. 14, 1147-1151, September 21, 1988
© 1988 Oxford University Press

Randomized Trial Comparing Aminoglutethimide With High-Dose Medroxyprogesterone Acetate in Therapy for Advanced Breast Carcinomau2

P. A. Canney*, T. J. Priestman, T. Griffiths, T. N. Latief, J. J. Mould, D. Spooner3,4

3Department of Radiotherapy, Queen Elizabeth Hospital, Edgbaston, Birmingham England B15 2TH.

*Correspondence to: P. A. Canney, M.D., Wessex Regional Radiotherapy Centre, Royal South Hants Hospital, Southampton, England SO9 4PE.

A total of 218 postmenopausal patients were entered in a prospective randomized trial comparing aminoglutethimide (AG) and high-dose medroxyprogesterone acetate (MPA) as second-line hormonal therapy for advanced breast carcinoma. All responses were assessed by the criteria of the International Union Against Cancer. The response rates were 27% (29 of 106 patients) for AG and 31% (35 of 112) for MPA, but if stabilization of previously progressive disease is included, then the overall response rates were 51% (54 of 106) and 54% (61 of 112) for patients receiving AG or MPA, respectively. There was no difference in response to the two drugs at any site of disease, and the durations of response and survival were identical for the two drugs. The time to response was significantly shorter for patients treated with MPA (median, 8.7 wk) than for those treated with AG (median, 15.3 wk) (x2=9.96, 1 df, P=.0016). The percentage of patients experiencing toxic effects was equivalent in both arms, although the patterns and time courses of these effects were different [J Natl Cancer Inst 1988;80:1147–151]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
D. Mauri, N. Pavlidis, N. P. Polyzos, and J. P. A. Ioannidis
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.
J Natl Cancer Inst, September 20, 2006; 98(18): 1285 - 1291.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.